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A B S T R A C T
Autism spectrum disorders (ASD) are a heterogeneous group of neuropsychiatric disorders
characterized by problems in social communication, as well as by the presence of
restricted interests, stereotyped and repetitive behaviours. In the last 40 years, genetic
studies have provided crucial information on the causes of ASD and its diversity. In this
article, I will ﬁrst review the current knowledge on the genetics of ASD and then suggest
three propositions to foster research in this ﬁeld. Twin and familial studies estimated the
heritability of ASD to be 50%. While most of the inherited part of ASD is captured by
common variants, our current knowledge on the genetics of ASD comes almost exclusively
from the identiﬁcation of highly penetrant de novo mutations through candidate gene or
whole exome/genome sequencing studies. Approximately 10% of patients with ASD,
especially those with intellectual disability, are carriers of de novo copy-number (CNV) or
single nucleotide variants (SNV) affecting clinically relevant genes for ASD. Given the
function of these genes, it was hypothesized that abnormal synaptic plasticity and failure
of neuronal/synaptic homeostasis could increase the risk of ASD. In addition to these
discoveries, three propositions coming from institutions, researchers and/or communities
of patients and families can be made to foster research on ASD: (i) to use more dimensional
and quantitative data than diagnostic categories; (ii) to increase data sharing and research
on genetic and brain diversity in human populations; (iii) to involve patients and relatives
as participants for research. Hopefully, this knowledge will lead to a better diagnosis, care
and integration of individuals with ASD.
 2016 Acade´mie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Autism spectrum disorders (ASD) are a group of
europsychiatric disorders characterized by problems in
ocial communication, as well as the presence of restricted
terests, stereotyped and repetitive behaviours [1,2]. Epi-
emiological studies estimate that more than 1% of the
opulation could receive a diagnosis of ASD [3]. Individuals
ith ASD can also suffer from other psychiatric and
edical conditions including intellectual disability (ID),
pilepsy, motor control difﬁculties, attention-deﬁcit hy-
eractivity disorder (ADHD), tics, anxiety, sleep disorders,
epression or gastrointestinal problems [4]. The term
SSENCE for ‘Early Symptomatic Syndromes Eliciting
eurodevelopmental Clinical Examinations’ was coined
y Christopher Gillberg to take into account this clinical
eterogeneity and syndrome overlap [4]. There are 4–8
mes more males than females in ASD, but the sex ratio is
ore balanced in patients with ID and/or dysmorphic
atures. Autism can be studied as a category (affected
s. unaffected) or as a quantitative trait using auto- or
etero-questionnaires such as the social responsiveness
cale (SRS) or the autism quotient (AQ). Using these tools,
utistic traits seem to be normally distributed in clinical
ases as well as in the general population.
The causes of autism remain largely unknown, but twin
tudies have constantly shown a high genetic contribution
 ASD. Molecular genetic studies have identiﬁed more
an 100 ASD-risk genes carrying rare and penetrant
eleterious mutations in approximately 10–25% of the
atients [5]. In addition, quantitative genetic studies have
shown that common genetic variants could capture almost
all the heritability of ASD [5]. The genetic landscape of ASD
is therefore shaped by a complex interplay between
common and rare variants and is most likely different
from one individual to another [6]. Remarkably, the
susceptibility genes seem to converge in a limited number
of biological pathways including chromatin remodelling,
protein translation, actin dynamics, and synaptic functions
[6].
In this chapter, I will detail the advances of the genetics
of ASD in the last four decades starting from twin studies,
following with molecular genetics and neurobiological
studies (Fig. 1) and end with propositions to foster research
in this ﬁeld.
2. Twin and family studies in ASD
Based on more than 13 twin studies, published between
1977 and 2015, researchers have estimated the genetic and
environmental contribution to ASD (Fig. 2). In 1977, the
ﬁrst twin study of autism by Folstein and Rutter reported a
cohort of 11 monozygotic (MZ) twins and 10 dizygotic (DZ)
twins. This study showed that MZ twins were more
concordant for autism in 36% (4/11) compared with 0%
(0/10) for DZ twins. When a ‘‘broader autism phenotype’’
was used, the concordance increased to 92% for MZ twins
and to 10% for DZ twins. Since this ﬁrst small-scale study,
twin studies have constantly reported higher concordance
for ASD in MZ compared with DZ twins. Between 2005 and
2009, three twin studies with relatively large group of
twins (up to more than 3000 twin pairs) have reported
R E´ S U M E´
Les troubles du spectre autistique (TSA) sont un groupe he´te´roge`ne de troubles
neuropsychiatriques caracte´rise´s par des proble`mes de communication sociale, ainsi
que par la pre´sence d’inte´reˆts restreints et de comportements ste´re´otype´s et re´pe´titifs. Au
cours des 40 dernie`res anne´es, les e´tudes ge´ne´tiques ont fourni des informations cruciales
sur les causes des TSA et leurs diversite´s. Dans cet article, je vais d’abord examiner les
connaissances actuelles sur la ge´ne´tique des TSA, puis sugge´rer trois propositions pour
encourager la recherche dans ce domaine. Les e´tudes familiales et de jumeaux ont permis
d’estimer l’he´ritabilite´ des TSA a` 50 %. Alors que la plupart de la partie he´rite´e des TSA est
due a` des variants communs, nos connaissances actuelles sur la ge´ne´tique des TSA vient
presque exclusivement de l’identiﬁcation de mutations de novo tre`s pe´ne´trantes a` l’aide
d’e´tudes de ge`nes candidats ou de se´quenc¸age d’exome/ge´nome entier. Environ 10 % des
patients atteints de TSA, en particulier ceux qui ont une de´ﬁcience intellectuelle, sont
porteurs de mutations de novo de nombre de copies (CNV) ou de changements de
nucle´otides (SNV) affectant des ge`nes cliniquement pertinents pour les TSA. Compte tenu
de la fonction de ces ge`nes, il a e´te´ e´mis l’hypothe`se qu’une plasticite´ synaptique anormale
et un de´faut de l’home´ostasie neuronale/synaptique pourrait augmenter le risque de TSA.
En plus de ces de´couvertes, trois propositions provenant des institutions, des chercheurs
et/ou des communaute´s de patients et des familles peuvent eˆtre formule´es pour
encourager la recherche sur les TSA : (i) utiliser des donne´es plus dimensionnelles et
quantitatives que les cate´gories de diagnostic ; (ii) augmenter le partage des donne´es et la
recherche sur la diversite´ ge´ne´tique et le cerveau dans les populations humaines ; (iii)
impliquer les patients et leurs familles en tant que participants a` la recherche. En espe´rant
que cette connaissance conduira a` de meilleurs diagnostics, de meilleurs soins et une
meilleure inte´gration des personnes atteintes de TSA.
 2016 Acade´mie des sciences. Publie´ par Elsevier Masson SAS. Cet article est publie´ en
Open Access sous licence CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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T. Bourgeron / C. R. Biologies 339 (2016) 300–307302gh concordances for ASD in MZ twins (77–95%)
mpared with DZ twins (31%). Interestingly, a signiﬁcant
oportion of the genetic contribution to ASD is shared
ith other neurodevelopmental disorders such as ADHD
 50%) and learning disability (> 40%) [7]. In summary,
when all twin studies are taken into account, concordance
for ASD is roughly 45% for MZ twins and 16% for DZ twins.
Family studies also revealed that the recurrence of
having a child with ASD increases with the proportion of
the genome that the individual shares with one affected
. 1. The history of the genetics of autism from 1975 to 2015. The increase in the number of genes associated with ASD (SFARI, March 2015) is represented
ether with the prevalence of ASD (data taken from the Center for Disease Control and Prevention), the different versions of the Diagnostic Statistical
nual (from DSM II to DSM-5.0), and the advance in genetics technology.
. 2. The main twins studies in ASD. A total of 13 twin studies and 17 heritability studies are depicted. Means of concordance and heritability weighted by
ple size are presented on the right-hand side of the ﬁgure.
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T. Bourgeron / C. R. Biologies 339 (2016) 300–307 303ibling or parent. In a population-based sample of
4,516 children diagnosed with ASD [8], the relative risk
r ASD (compared to the general population) was
stimated to be 153.0 (95% conﬁdence interval (CI):
6.7–412.8) for MZ twins, 8.2 (3.7–18.1) for DZ twins,
0.3 (9.4–11.3) for full siblings, 3.3 (95% CI: 2.6–4.2) for
aternal half siblings, 2.9 (95% CI: 2.2–3.7) for paternal
alf siblings, and 2.0 (95% CI: 1.8–2.2) for cousins. The
eritability was estimated to be 50% (95% CI: 45–56), and
e non-shared environmental inﬂuence was also 50%
5% CI: 44–55). Surprisingly, only the additive genetic
omponent and the non-shared environment seemed to
ccount for the risk to develop ASD [8].
In summary, epidemiological studies have provided
rucial information on the heritability of ASD. However,
ey do not inform us on the genes involved or on the
umber and frequency of their variants. In the last
5 years, candidate genes and whole-genome analyses
ave been performed to address these questions.
. From chromosomal rearrangements to copy-number
ariants in ASD
The ﬁrst genetic studies that associated genetic variants
ith autism used observations from cytogenetic studies.
owever, because of the low resolution of the karyotypes,
 was almost impossible to associate a speciﬁc gene with
SD using this approach. The prevalence of large chromo-
omal abnormalities is estimated to be less than 2%.
hanks to progress in molecular technologies, the resolu-
on in the detection of genomic imbalances has dramati-
ally increased. Nowadays, the copy-number variants
NVs)—that are small gain or loss of genomic DNA—are
obustly detected. De novo CNVs are present in 4–7% of the
atients with ASD compared with 1–2% in unaffected
iblings and controls [9]. Beyond ASD, large CNVs
 400 kb) affecting genes are present in 15% of patients
ith developmental delay (DD) or ID. Most of the CNVs are
rivate to each individual, but some are recurrently
bserved in independent patients. The studies have also
dicated that de novo CNVs identiﬁed in patients with ASD
re most likely altering genes associated with synaptic
nctions [9].
In summary, large chromosomal rearrangements and
NVs increase the risk of having ASD in 5–10% of the
dividuals. In order to go further in the identiﬁcation of
e ASD-risk genes, candidate genes and whole exome/
enome sequencing studies were performed.
. From candidate genes to whole exome/genome
equencing studies in ASD
The ﬁrst approach to associate a gene with ASD was to
elect speciﬁc candidate genes based on data coming from
nctional or genetic studies or a combination of both. This
pproach was successful in identifying several synaptic
enes associated with ASD such as NLGN3, NLGN4X and
HANK3 [10,11]. Thanks to the advance in next-generation
equencing (NGS), we can now interrogate all genes of the
enome in an unbiased manner using whole exome/
enome sequencing (WES, WGS). These approaches allow
the identiﬁcation of virtually all the mutations within
genes carried by an individual.
To date, more than 18 of such WES/WGS studies have
been performed, comprising altogether more than
4000 families. Based on these studies, 3.6–8.8% of the
patients were shown to carry a de novo causative mutation
with a twofold increase of deleterious mutations in the
patients compared with their unaffected siblings. In a
meta-analysis, using more than 2500 families, Iossifov
et al. [12] found that de novo likely gene disrupting
mutations (frameshift, nonsense and splice site) were
more frequent in patients with ASD compared with
unaffected siblings (P = 5  107). The carriers of these
de novo mutations were more likely diagnosed with a low
non-verbal IQ. Interestingly, the mutations were signiﬁ-
cantly enriched in genes involved in chromatin modelling
factors (P = 4  106) and in genes regulated by the fragile
X syndrome protein (FMRP) complex (P = 4  107).
Only few studies have analysed the contribution of
recessive inherited mutations in ASD. It was estimated that
likely gene disrupting mutations (present on both paternal
and maternal chromosomes) could account for 3% of the
patients with ASD. For the X chromosome, there was a
signiﬁcant 1.5-fold increase in complete loss of function
mutations in affected males compared to unaffected males,
who could account for 2% of males with ASD [13].
5. The common variants in ASD
In the general population, one individual carries on
average 3 million genetic variants in comparison to the
reference human genome sequence. The vast majority of the
variants (> 95%) are the so-called common variants shared
with more than 5% of the human population. Using
quantitative genetics, it was estimated that common
variants were contributing to a high proportion of the
liability of ASD: 40% in simplex families and 60% in multiplex
families. In 2014, the study of Gaugler et al. provided an
estimation of the heritability (52.4%), which is almost
exclusively due to common variation, leaving only 2.6% of
the liability to the rare variants [14]. These results indicate
that the contribution of common variants is important, but
the causative SNPs still remain unknown since they are
numerous (> 1000) and each associated with a low risk. To
date, the largest genome wide association studies (GWAS)
performed on < 5000 families with ASD were underpow-
ered to identify a single SNP with genome wide signiﬁcance.
The recruitment of larger cohorts of patients with dimen-
sional phenotypes is warranted to better ascertain the
heritability of ASD and to identify the genetic variants,
which explain most of the genetic variance.
6. The genetic architecture of ASD: an interplay between
rare and common variants
Based on the results coming from epidemiological and
molecular studies, it is now well accepted that genetic
factors play an important role in the susceptibility to ASD.
It was also shown that the genetic susceptibility to ASD
could be different from one individual to another with a
combination of rare deleterious variants and a myriad of
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r some individuals, a single de novo mutation will be
ough to cause autism. For some individuals, the
cumulation of many (> 1000) common risk alleles will
ditively increase the risk of autism.
The interplay between the rare or de novo variants and
e background will also inﬂuence the phenotypic
versity observed in the patients carrying rare deleterious
utations. In some individuals, a genetic background will
 able to buffer or compensate the impact of the rare
netic variations. In contrast, in some individuals, the
ffering capacity of the genetic background will not be
fﬁcient to compensate the impact of the deleterious
utations and they will develop ASD. In this model, ASD
n be regarded as a collection of many genetic forms of
tism, each with a different aetiology ranging from
onogenic to polygenic models.
Fortunately, although the ASD-risk genes are numer-
s, they seem to converge in a limited number of
ological pathways that are currently scrutinized by many
searchers.
 The biological pathways associated with ASD
Based on results from the genetics of ASD, cellular and
imal models have been analysed in order to identify the
ain mechanisms leading to this complex syndrome.
markably, several studies showed that neuronal activity
ems to regulate the function of many of the ASD-risk
nes. This has led to the hypothesis that abnormal
naptic plasticity and failure of neuronal/synaptic ho-
eostasis could play a key role in the susceptibility to ASD.
. 3 summarizes the main gens/pathways associated
ith ASD: chromatin remodelling, protein synthesis, protein
gradation, and synaptic function (Fig. 3).
 Perspectives: three propositions to improve research
 autism
While tremendous progress has been made in the
derstanding of the causes of autism, I will detail three
opositions that could foster the research in the ﬁeld.
. Proposition #1: fewer categories, more dimensions
The recent advances in genomics have demonstrated
at an identical genetic variant may increase the risk for a
ide range of diagnoses formerly thought of as distinct.
ese ﬁndings are contributing to a re-conceptualization of
e current psychiatric nosology. The ﬁfth edition of the
agnostic and Statistical Manual (DSM-5) from the
erican Psychiatric Association now makes it easier to
cognize overlap between different diagnostic categories,
t in the main, the existing narrow and rigid categories
nd to disconnect researchers from the real phenotypes.
cently, several initiatives such as the ESSENCE from
ristopher Gillberg were undertaken to improve pheno-
pe characterization using more dimensional approaches.
e Research Domain Criteria (RDoC) has been launched
 NIMH calling for the development, for research purposes,
dimensions of observable behaviour and neurobiological
and genetic measures (http://www.nimh.nih.gov/
research-priorities/rdoc/nimh-research-domain-criteria-
rdoc.shtml). This effort is attempting to deﬁne basic
dimensions of functioning related to known neural circuitry
to be studied across multiple units of analysis, from genes to
neural circuits to behaviours, cutting across disorders as
traditionally deﬁned.
In summary, it is most likely that progress in the
comprehension of the risk factors for autism will come
from dimensional and quantitative data that goes well
beyond current psychiatric classiﬁcation. One ﬁrst step
would be to gather the information that is currently
separated by DSM-5 diagnostic categories and dispersed in
different laboratories that may fail to communicate. To
achieve this, there is a need of more data sharing (see
below).
8.2. Proposition #2: more research on genetic and brain
diversity in human populations and more data sharing
Based on current case-control design, there is a
tendency for researchers to know better the genotypes
and phenotypes of the patients than those of the controls.
Indeed, in the vast majority of the genetic studies, controls
are often not investigated at the phenotypic level, and in
phenotypic studies, controls are very limited in their
number and cultural and social economic status diversity.
As a consequence, early onset developmental disorders are
therefore considered as binary traits ‘‘affected’’ vs. ‘‘non-
affected’’ without taking into account the genetic and
phenotypic diversity of both ‘‘affected’’ and ‘‘non-affected’’
individuals.
Integrating diversity in our experimental design will
require increasing the sample size of our study popula-
tions. Indeed, risk factors for early onset neurodevelop-
mental disorders are either rare with large effect or
frequent, but with a small effect. In both situations, robust
genotype–phenotype relationships are difﬁcult to ascer-
tain in small samples. One opportunity to increase sample
size is to foster data sharing. Many brakes reduce efﬁcient
data sharing. Hence, there is a need:
 to agree on an ethical informed consent for research
subjects that will allow data sharing;
 to agree on standardized measures;
 to change the reward system regarding publications;
 to set up a system to make data sharing easy and secure.
There is an emerging community of researchers
involved in data sharing. Speciﬁcally in neuroscience,
initiatives such as the Neuroscience Information Frame-
work (NIF) or the International Neuroinformatics Coordi-
nating Facility (INCF) were launched recently. NIF (http://
www.neuinfo.org) is a dynamic inventory of Web-based
neuroscience resources: data, materials, and tools accessi-
ble via any computer connected to the Internet. This
should advance neuroscience research by enabling discov-
ery and access to public research data and tools worldwide
rough an open source, networked environment. INCF new ways of classifying psychopathology based on th
Fig. 3. Examples of the biological pathways associated with ASD. The ASD-risk genes code for proteins involved in chromatin remodeling, transcription,
protein synthesis, and degradation, cytoskeleton dynamics, and synaptic functions. Proteins associated with ASD are circled in red.
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rmatics infrastructure and promotes the sharing of data
d computing resources with the international research
mmunity.
. Proposition #3: patients and relatives as participants for
search
Many aspects on the quality of life of the patients and
eir relatives are not adequately taken into account by
searchers. For example, in ASDs, comorbidities such as
strointestinal and sensory problems are under-explored.
e movement ‘‘no research about me, without me’’ is
lling for patients and their relatives to be more involved
 research designs. For example, the UK National health
rvice (NHS) initiative INVOLVE (http://www.invo.org.
) is a national advisory group that supports greater
blic involvement in NHS, public health and social care
search. There is also the James Lind Alliance (http://
ww.lindalliance.org), the Patient-Centered Outcomes
search Institute (PCORI; http://www.pcori.org), and
tientsLikeMe (http://www.patientslikeme.org) initiati-
s for patients that want to monitor their own health and
ronic illness. Another example is the initiative for Cancer
search at Sage Bionetworks (http://www.sagebase.org).
GE develops tools so that medical patients can keep their
n data rather than storing that data in particular
edical institutions. The aim is to offer predictive,
rsonalized, preventive, participatory (P4) medicine.
 Conclusion: towards a more inclusive world
In the last 40 years, very signiﬁcant progresses were
ade in the genetics of ASD. We have now a better
owledge of the genetic architecture of this heterogeneous
ndrome and some of the biological pathways are now
vestigated using different approaches such as cellular and
imal models. There are however many aspects of the
netics of ASD that remain largely unknown.
The ﬁrst challenge concerns the role of the common
riants. These variants are most likely playing a key role in
e susceptibility to ASD and in the severity of the
mptoms. But, because the impact of each single SNP is
ry low, it is currently impossible to identify the risk alleles
ing conventional GWAS. In human quantitative traits such
 height, neuroanatomical diversity or intelligent quotient,
ry large cohorts of many thousands of individuals are
cessary to identify the main causative SNPs.
The second challenge concerns the stratiﬁcation of the
tients and the role of the ASD-risk genes during brain
velopment/function. Based on our current knowledge,
e genetic architecture of ASD seems to be different from
e individual to another with possibly contrasting impact
 when and where neuronal connectivity could be
ypical compared to the general population. For example,
 animal models, several mutations lead to higher
nnectivity whereas other mutations alter synaptic
nsity. It is therefore crucial to increase our knowledge
m a basic research perspective on the biological roles of
Finally, while we all agree that biological research is
necessary to improve the quality of life of the patients and
their families, progress should also be made for a better
recognition and inclusion of people with neuropsychiatric
conditions in our societies (no mind left behind). For
patients, the burden of neurodevelopmental disorders
makes daily activities difﬁcult and lowers the odds of
living an independent life. In addition to improved
medical care, innovative initiatives towards a more
inclusive world point toward other important advances.
For example, Aspiritech (http://www.aspiritech.org), a
non-proﬁt organization based in Highland Park, Illinois,
places people who have autism (mainly Asperger’s
syndrome) in software testing jobs. The Danish company
Specialisterne has helped more than 170 individuals with
autism obtain jobs since 2004. Its parent company, the
Specialist People Foundation, aims to connect one million
autistic people with meaningful work (http://www.
specialistpeople.com). Laurent Mottron, a psychologist
working in Montre´al, has offered jobs for patients with
ASD in his group and this new perspective has had a
positive impact on his research on autism. As he said, ‘‘The
hallmark of an enlightened society is its inclusion of non-
dominant behaviours and phenotypes, such as homosex-
uality, ethnic differences and disabilities. Governments
have spent time and money to accommodate people with
visual and hearing impairments, helping them to navigate
public places and ﬁnd employment, for instance—we
should take the same steps for autistics’’ [15]. As
suggested by Gillberg, it might be better to abandon the
belief that there is a single deﬁning ASD brain dysfunction.
Instead, we should understand the diversity of ASD (or
autisms). Considering autism not as a single entity, but as
a continuum of human diversity and tackling this
heterogeneity using information coming from different
ﬁelds of research (including direct information from the
affected individuals and their family) should allow a
better diagnosis, care and integration of individuals with
autism [15].
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